HCC, Radiofrequency Ablation, Sorafenib
Conditions
Brief summary
RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC. So the investigators hypothesized that combined RFA and Sorafenib might reduce the frequency of recurrence and improve the overall survival and disease free survial.
Interventions
OTHERRFA + Sorafenib
combined RFA and Sorafenib to treat recurrent HCC
OTHERRFA
treat Recurrent HCC with RFA
Sponsors
Hunan Province Tumor Hospital
Tang-Du Hospital
Xijing Hospital
First Affiliated Hospital of Guangxi Medical University
First Affiliated Hospital Xi'an Jiaotong University
Anhui Provincial Hospital
Xiangya Hospital of Central South University
Xinqiao Hospital of Chongqing
Xinjiang Tumor Hospital
People's Hospital of Guangxi Zhuang Autonomous Region
Henan Cancer Hospital
People's Hospital of Sichuan
Huaxi Hospital
Southwest Hospital, China
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* recurrent HCC after curative resection * without gender restriction * age between 18 to 75 years * The liver function showed no worse than Child-Pugh B * tumor nodes were less than 5cm and no more than 3 nodules
Exclusion criteria
* Pregnancy patients * With extrahepatic tumor or lymphnode metastasis * Tumor invasion or thrombosis in portal vein,hepatic vein or inferior vena cava
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time interval between new lessions emerging after the first HCC recurrence | 3 year |
Secondary
| Measure | Time frame |
|---|---|
| 3-year overrall survival | 3 year |
Countries
China
Contacts
Primary ContactXiaobin Feng, MD
Outcome results
None listed